Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532695 | 1.00 | MEN1 (0.59) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL9824790 | 0.96 | EPHX1 (0.56) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL10709444 | 0.96 | MEN1 (0.60) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL10706722 | 0.96 | MEN1 (0.60) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| Hydrochloric Acid SCHEMBL11096519 | 0.95 | MEN1 (0.62) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL18381212 | 0.93 | TAAR1 (0.62) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL24322439 | 0.93 | TAAR1 (0.62) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL2089398 | 0.89 | HTR2C (0.60) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL2089397 | 0.89 | HTR2C (0.60) | MEN1KMT2AEPHX1TAAR1HTR2C | |
| SCHEMBL2089855 | 0.89 | HTR2C (0.60) | MEN1KMT2AEPHX1TAAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | MEN1 786/4885KMT2A 3149/4885EPHX1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.